Degarelix (CAS 214766-78-6) – Research Grade is a high-purity chemical compound.

Degarelix is a polypeptide.

Research Context

Research Applications

Degarelix is primarily studied for its application in the treatment of prostate cancer. It functions as a gonadotropin-releasing hormone (GnRH) antagonist, effectively reducing testosterone levels, which is crucial in managing hormone-sensitive malignancies. The therapeutic area of prostate cancer has been the focus of clinical and preclinical research, particularly in patients who exhibit advanced stages of the disease.

Degarelix is FDA-approved under the trade name Firmagon for the treatment of advanced prostate cancer. Its use has been pivotal in hormone therapy, providing an alternative to traditional GnRH agonists, which can initially increase testosterone levels before causing a decline.

History & Development

Degarelix was originally developed by the pharmaceutical company Ferring Pharmaceuticals in the early 2000s. The drug received FDA approval in 2008 for the treatment of advanced prostate cancer, marking a significant milestone in the management of this disease. The trade name under which it is marketed is Firmagon.

Notably, Degarelix features a modified amino acid sequence that enhances its resistance to enzymatic degradation, allowing for a more prolonged therapeutic effect compared to other GnRH analogs. This design feature contributes to its rapid onset of action and sustained suppression of testosterone levels.

Mechanism of Action

Degarelix operates at the cellular level by binding to GnRH receptors in the pituitary gland. Unlike GnRH agonists, which initially stimulate testosterone production, Degarelix antagonizes these receptors, leading to a direct suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. This results in a rapid decrease in testosterone production from the testes, effectively lowering serum testosterone levels within days of administration.

The rapid onset of action and sustained testosterone suppression make Degarelix a valuable option in the management of prostate cancer, particularly for patients requiring immediate hormonal control.

Clinical Data

Clinical studies have demonstrated the efficacy of Degarelix in the management of advanced prostate cancer. For instance, a pivotal Phase 3 trial conducted by Klotz et al. published in the New England Journal of Medicine showed that patients treated with Degarelix experienced a significant reduction in testosterone levels within three days, compared to those treated with a GnRH agonist. Additionally, published studies suggest that Degarelix maintains testosterone suppression for at least 12 months, which is critical for effective disease management.

Another study by Klotz et al. indicated that the use of Degarelix resulted in a lower incidence of testosterone flare compared to traditional therapies, supporting its role as a preferred treatment option for patients with advanced prostate cancer.

How It Compares

When compared to related compounds such as GnRH agonists like Leuprolide and Triptorelin, Degarelix offers a distinct advantage in its mechanism of action. While GnRH agonists initially stimulate testosterone release before causing suppression, Degarelix provides immediate inhibition of testosterone production, significantly reducing the risk of testosterone flare.

In contrast to other GnRH antagonists, such as Elagolix, which is primarily used for endometriosis, Degarelix's specific application in prostate cancer highlights its unique therapeutic role. The half-life of Degarelix allows for less frequent dosing compared to some other peptides, making it a practical choice for long-term management of hormone-sensitive cancers.

Solubility & Storage

Degarelix is typically reconstituted using sterile water for injection or bacteriostatic water. It is essential to follow proper reconstitution techniques to maintain the integrity of the peptide. Once reconstituted, Degarelix should be stored in a refrigerator at temperatures between 2°C to 8°C (36°F to 46°F) and used within 28 days to ensure efficacy.

The lyophilized form of Degarelix, prior to reconstitution, can be stored at room temperature, away from direct sunlight, for up to 24 months. Proper storage conditions are critical to preserving the peptide's stability and effectiveness.

Future Research Directions

Future research on Degarelix is exploring its potential applications beyond prostate cancer, including its off-label use in treating hormone-related disorders. Investigations are focusing on the long-term effects of GnRH antagonism and its implications in other hormone-sensitive cancers.

Emerging studies are also assessing the combination of Degarelix with other therapeutic agents to enhance treatment efficacy and minimize side effects. As ongoing clinical trials continue to unveil new data, the role of Degarelix in cancer therapy may expand, offering additional insights into its therapeutic potential.